DETAILED ACTION
Claims 89-107 are pending in the instant application.
2. Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
(a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention.
Claims 89, 93-107 are rejected under 35 U.S.C. 102(a)(1) and 102(a)(2) as being anticipated by Almansa et al., WO 2004076450. Almansa et al. discloses on page 29, p38 kinase inhibitors, inducing reduction of proinflammatory cytokines. P38 kinase can treat immune, autoimmune and inflammatory disease, neurodegenerative disease. Therefore, the instant claims are anticipated by Almansa et al.
3. Claim Rejections - 35 USC § 112
The following is a quotation of the first paragraph of 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claims 89, 93-107 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim contains subject matter, which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. The specification lacks enablement of the term “p38MAP kinase inhibitor”, which are claimed in the method claims. While enabling for “p38MAP kinase inhibitor” example in claims 90-93, formula (I), formula (II), formula (III), it is not seen this is enables for other types of “p38MAP kinase inhibitor”. Therefore, the specification lacks enablement for the term ““p38MAP kinase inhibitor” other than formula (I), formula (II), formula (III) in claims 90-93.
4. Claim Objections
Claims 90-92 are objected to as being dependent upon a rejected base claim 89, but would be allowable if rewritten in independent form including all of the limitations of the base claims and any intervening claims.
5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Niloofar Rahmani whose telephone number is
571-272-4329. The examiner can normally be reached on Monday through Friday from 8:30 am to 5:00 pm.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Renee Claytor, can be reached on 571-272-8394. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).
/NILOOFAR RAHMANI/
05/05/2026
Prosecution Insights